Preventive effect of risedronate on bone loss in men receiving androgen‐deprivation therapy for prostate cancer

Abstract

Aim: Androgen-deprivation therapy for prostate cancer decreases bone mineral density and increases the risk of fracture. The effect of risedronate, a potent third-generation oral bisphosphonate, on bone loss during androgen deprivation therapy was investigated. Methods: Sixty-one prostate cancer patients with a mean age (ϮSD) of 79 Ϯ 6 years who had received androgen deprivation therapy for 42 Ϯ 29 months were enrolled , and were treated with 2.5 mg of risedronate daily for six months. Bone mineral density was measured at the femoral neck, lumbar spine, and ultradistal radius by dual energy X-ray absorptiometry. The percent change of bone mineral density after treatment with risedronate was calculated as the primary efficacy variable. Urinary N-telopeptide of type I collagen was measured as a bone resorption marker. Results: Bone mineral density remained stable in the femoral neck and radius during risedronate therapy. In contrast, the bone mineral density of the lumbar spine showed a significant increase from 1069 Ϯ 488 mg/cm 2 -1112 Ϯ 497 mg/cm 2 (P < 0.001), representing a gain of 4.9 Ϯ 8.9%. Urinary N-telopeptide of type I collagen decreased significantly (P < 0.001) after three months of risedronate treatment. Conclusions: Risedronate could prevent and reverse bone loss in men receiving androgen deprivation therapy for prostate cancer by inhibiting bone resorption.

Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study

“…16 On the other hand, oral bisphosphonates including risedronate also have been developed for their convenient administration. Ishizaka et al 17 reported that risedronate prevented bone loss of the femoral neck and can reverse bone loss of the lumbar spine in men receiving ADT for PCa. This was the first report confirming the effect of risedronate on bone loss in PCa patients treated with ADT.…”

Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone‐releasing hormone‐agonist therapy for prostate cancer

“…[13] showed that risedronate prevented bone loss of the femoral neck and can reverse bone loss of the lumbar spine in men receiving ADT for prostate cancer. Sixtyone men with a mean ( SD ) age of 79 (6) years who had been on ADT for 42 (29) months were treated with 2.5 mg oral risedronate daily for 6 months.…”

Androgen Deprivation Therapy for Prostate Cancer

“…The effect on the reduction of osteoporotic fractures has been demonstrated for treatment with alendronate, risedronate, ibandronate, etidronate and zoledronic acid. The effectiveness in reducing vertebral and nonvertebral fractures were confirmed by many studies (73,74,75). The optimal regimen for zoledronic acid is unclear, because one study recommends treatment every 3 weeks (76), while another trial has produced similar results with an annual injection (77), and finally, another study reports that single infusion of zoledronic acid in patients receiving ADT reduces bone mineral loss and maintains BMD at least for 12 months during ADT (78).…”